SG10201902850TA - Human-derived anti-dipeptide repeats (dprs) antibody - Google Patents

Human-derived anti-dipeptide repeats (dprs) antibody

Info

Publication number
SG10201902850TA
SG10201902850TA SG10201902850TA SG10201902850TA SG10201902850TA SG 10201902850T A SG10201902850T A SG 10201902850TA SG 10201902850T A SG10201902850T A SG 10201902850TA SG 10201902850T A SG10201902850T A SG 10201902850TA SG 10201902850T A SG10201902850T A SG 10201902850TA
Authority
SG
Singapore
Prior art keywords
dprs
antibody
human
dpr
derived anti
Prior art date
Application number
SG10201902850TA
Inventor
Fabio Montrasio
Jan Grimm
Original Assignee
Neurimmune Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Holding Ag filed Critical Neurimmune Holding Ag
Publication of SG10201902850TA publication Critical patent/SG10201902850TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Abstract

Human-derived anti-dipeptide repeats (DPRs) antibody 5 Provided are novel human-derived dipeptide repeat (DPR) specific antibodies as well as synthetic variants and biotechnological derivatives thereof, preferably capable of binding C9ORF72 DPRs, as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for DPRs and DPR proteins such C9ORF72 DPRs are also disclosed. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions 10 for DPR protein-targeted immunotherapy and diagnostics. [No suitable Figure]
SG10201902850TA 2014-09-30 2015-09-30 Human-derived anti-dipeptide repeats (dprs) antibody SG10201902850TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14187180 2014-09-30
EP15180310 2015-08-07

Publications (1)

Publication Number Publication Date
SG10201902850TA true SG10201902850TA (en) 2019-04-29

Family

ID=54238439

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201902850TA SG10201902850TA (en) 2014-09-30 2015-09-30 Human-derived anti-dipeptide repeats (dprs) antibody
SG11201701925XA SG11201701925XA (en) 2014-09-30 2015-09-30 Human-derived anti-dipeptide repeats (dprs) antibody

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201701925XA SG11201701925XA (en) 2014-09-30 2015-09-30 Human-derived anti-dipeptide repeats (dprs) antibody

Country Status (17)

Country Link
US (2) US10392447B2 (en)
EP (1) EP3201228A2 (en)
JP (3) JP6637971B2 (en)
KR (2) KR20230104759A (en)
CN (1) CN108064248B (en)
AU (2) AU2015326911B2 (en)
BR (1) BR112017006598A2 (en)
CA (1) CA2960925A1 (en)
CO (1) CO2017002804A2 (en)
IL (2) IL278941B (en)
MX (1) MX2017004213A (en)
MY (1) MY180054A (en)
NZ (1) NZ729808A (en)
PH (1) PH12017500489A1 (en)
SG (2) SG10201902850TA (en)
WO (1) WO2016050822A2 (en)
ZA (2) ZA201701733B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2888486A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
SG11201602597YA (en) 2013-10-11 2016-05-30 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
WO2016050822A2 (en) 2014-09-30 2016-04-07 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
EP3797114A4 (en) * 2018-04-27 2022-05-11 Biogen MA Inc. Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody
AU2019354291A1 (en) * 2018-10-01 2021-05-06 United Neuroscience Peptide immunogen constructs directed against dipeptide repeat proteins from C9ORF72
MA54070A (en) 2018-10-29 2021-09-08 Biogen Ma Inc HUMANIZED AND STABILIZED FC5 VARIANTS FOR ENHANCED TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER
WO2020107037A1 (en) * 2018-11-25 2020-05-28 President And Fellows Of Harvard College Compounds and methods for treating neurodegenerative diseases
KR20210102294A (en) 2018-12-06 2021-08-19 바이오젠 엠에이 인코포레이티드 Neurofilament proteins to guide therapeutic interventions in amyotrophic lateral sclerosis
CN110470837B (en) * 2019-08-30 2022-09-16 苏州西山生物技术有限公司 Method for detecting simian SRV by using simian SRV GP20 protein and kit thereof
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology Method for enhancing glycoprotein stability.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE120761T1 (en) 1987-05-21 1995-04-15 Creative Biomolecules Inc MULTIFUNCTIONAL PROTEINS WITH PREDEFINED TARGET.
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
DE68921982T4 (en) 1988-06-14 1996-04-25 Cetus Oncology Corp COUPLING AGENTS AND STERICALLY DISABLED CONJUGATES THEREOF.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ATE381614T1 (en) 1992-07-24 2008-01-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE236987T1 (en) 1992-11-13 2003-04-15 Idec Pharma Corp CONSENSUS KOZAK SEQUENCES FOR MAMMAL EXPRESSION
ES2304786T3 (en) 1995-04-27 2008-10-16 Amgen Fremont Inc. ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
RO120148B1 (en) 1997-03-14 2005-09-30 Idec Pharmaceuticals Corporation Vector system and method for integrating a dna fragment in the mammalian cells genome
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
CN1306272C (en) 2000-11-17 2007-03-21 罗切斯特大学 In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002060955A2 (en) 2001-01-29 2002-08-08 Idec Pharmaceuticals Corporation Modified antibodies and methods of use
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
CN1871259A (en) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 Improved antibodies having altered effector function and methods for making the same
AU2007222798A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CN103408661B (en) 2007-01-05 2016-04-06 苏黎世大学 The method of disease-specific binding molecules and target is provided
US8709382B2 (en) * 2007-01-11 2014-04-29 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US9023351B2 (en) * 2007-11-26 2015-05-05 Bayer Intellectual Property Gmbh Anti-mesothelin antibodies and uses thereof
WO2012118903A2 (en) * 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
CN103796678B (en) * 2011-04-20 2018-02-27 健玛保 For HER2 bispecific antibody
WO2012158948A1 (en) * 2011-05-17 2012-11-22 The Rockefeller University Human immunodeficiency virus neutralizing antibodies adn methods of use thereof
WO2013071175A1 (en) * 2011-11-11 2013-05-16 Alere San Diego, Inc. Devices and methods for detection of panton-valentine leukocidin (pvl)
WO2014114303A1 (en) * 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
PL2948777T3 (en) * 2013-01-22 2019-12-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
EP2948471A4 (en) 2013-01-24 2016-08-10 Mayo Foundation Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
JP6628285B2 (en) 2013-03-14 2020-01-08 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド ALS-related diamino acid repeat-containing protein
WO2016050822A2 (en) 2014-09-30 2016-04-07 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
AU2021245147A1 (en) 2021-11-04
CN108064248B (en) 2022-03-15
US10961322B2 (en) 2021-03-30
PH12017500489A1 (en) 2017-08-07
BR112017006598A2 (en) 2018-04-17
ZA201701733B (en) 2021-09-29
SG11201701925XA (en) 2017-04-27
KR20230104759A (en) 2023-07-10
NZ729808A (en) 2022-02-25
MX2017004213A (en) 2017-07-19
CO2017002804A2 (en) 2017-06-20
AU2015326911B2 (en) 2021-07-08
KR20170061702A (en) 2017-06-05
IL278941B (en) 2022-07-01
EP3201228A2 (en) 2017-08-09
MY180054A (en) 2020-11-20
IL251081A0 (en) 2017-04-30
JP2021177788A (en) 2021-11-18
AU2015326911A1 (en) 2017-03-30
JP6637971B2 (en) 2020-01-29
US10392447B2 (en) 2019-08-27
CA2960925A1 (en) 2016-04-07
IL278941A (en) 2021-01-31
WO2016050822A3 (en) 2016-06-02
US20200010567A1 (en) 2020-01-09
JP2020031660A (en) 2020-03-05
CN108064248A (en) 2018-05-22
US20170247471A1 (en) 2017-08-31
WO2016050822A2 (en) 2016-04-07
KR102594327B1 (en) 2023-10-27
JP2017538665A (en) 2017-12-28
ZA201808270B (en) 2022-04-28

Similar Documents

Publication Publication Date Title
PH12017500489A1 (en) Human-derived anti-dipeptide repeats (dprs) antibody
PH12021550083A1 (en) Human anti-tau antibodies
MX2020011312A (en) Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody.
MX365387B (en) Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof.
PH12018501882A1 (en) Binding proteins and methods of use thereof
MY167795A (en) Tdp-43 specefic binding molecules
MX345092B (en) Human anti-tau antibodies.
WO2014200910A3 (en) Bioinformatic processes for determination of peptide binding
CU20180024A7 (en) THERMAL STROMAL LYMPHOPYETIN BINDING MOLECULES (TSLP), PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND THE SAME PRODUCTION METHOD
EA201890655A1 (en) MOLECULES ASSOCIATED WITH THYMUSIC STROMAL LYMPHOPOETHIN (TSLP) AND METHODS OF APPLICATION OF SUCH MOLECULES
MX2022003704A (en) Human-derived anti-huntingtin (htt) antibodies and uses thereof.
MX346500B (en) Methods and compositions for neural disease immunotherapy.
WO2016014612A3 (en) Compositions and methods for the diagnosis of rheumatoid arthritis
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
EP4273235A3 (en) Anti-bed bug monoclonal antibodies and methods of making and uses thereof
WO2016090163A3 (en) Anti-acetaminophen antibodies and acetaminophen protein adducts
GB2541596A (en) Method and composition for determining specific antibody responses to species of filovirus
WO2015153949A3 (en) Compositions and methods for identifying ehrlichia species
EA201790433A1 (en) ORIGINAL FROM HUMAN ANTIBODY TO DIPEPTID REPEATERS (DPR)
WO2016001424A3 (en) Human-derived anti-human il-20 antibodies and assay for the identification of anti-cytokine antibodies